Biogen Idec Inc (BIIB) 417.63 $BIIB
Could This Study Help Lead to a Cure for Select Multiple Sclerosis Patients?
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 08, 8:12AM CDT
Source: National Multiple Sclerosis Society, Facebook For a disease that affects 2.5 million people around the globe and more than 400,000 people in the United States, it's a shame that so little is known about multiple sclerosis despite the amount...
BIIB: 417.63 (-7.98), RCPT: 140.09 (-1.10)
2 Tiny Biotechs That Could Have Blockbuster Opportunity
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Sat Mar 07, 9:11AM CST
Smaller health care stocks are not for the faint of heart. When it comes to developing and testing new drugs, the success rate is tiny but the rewards can be huge. How can the risk-tolerant Fool spot the next Amgen or Biogen ? This health care...
JNJ: 100.11 (-2.41), BIIB: 417.63 (-7.98), PTLA: 41.72 (-0.13), PFE: 33.97 (-0.50), OPHT: 53.19 (-0.29), AMGN: 154.88 (-4.72), BMY: 65.12 (-0.93), NVS: 97.46 (-1.49), CELG: 118.03 (-2.68)
Top 5 IBD 50 Drug Stocks Thriving Via Acquisitions
at Investor's Business Daily - Sat Mar 07, 7:02AM CST
The recent flurry of deal-making in the drug sector has put the spotlight on other top-rated drugmakers that have grown with the help of savvy mergers and acquisitions. In just the past week, AbbVie (ABBV) agreed to buy Pharmacyclics (PCYC) for $21...
AGN: 233.51 (-1.90), MNK: 121.33 (-0.37), JNJ: 100.11 (-2.41), BIIB: 417.63 (-7.98), ACT: 289.92 (-5.78), VRX: 198.71 (-5.24), PCYC: 254.56 (+0.34), OMED: 27.55 (-0.12), AKRX: 49.83 (-1.05), SLXP: 158.01 (+0.57), ABBV: 55.64 (-1.22), CELG: 118.03 (-2.68)
ISIS Pharmaceuticals Has The Cash To Develop Its Expanding Product Pipeline
Emerging Equities - at Seeking Alpha - Fri Mar 06, 4:03PM CST
BIIB: 417.63 (-7.98), ISIS: 70.44 (-1.32), IBB: 342.36 (-5.31), GSK: 46.73 (-0.87), ETF: 12.82 (-0.18)
Stock Market News for March 06, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Mar 06, 9:10AM CST
Markets snapped a two-day losing streak on Thursday, somewhat boosted by the ECB announcing a trillion-dollar stimulus plan that will kick off on Monday
BIIB: 417.63 (-7.98), JNJ: 100.11 (-2.41), PCYC: 254.56 (+0.34), ADP: 86.00 (-0.75), MDT: 76.48 (-2.02), GILD: 101.81 (-1.61), ABBV: 55.64 (-1.22), BMY: 65.12 (-0.93)
Isis Pharma earns $9M milestone from Biogen
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 8:28AM CST
BIIB: 417.63 (-7.98), ISIS: 70.44 (-1.32)
5 Top Medical Stocks: How To Read Their Chart Action
at Investor's Business Daily - Thu Mar 05, 5:32PM CST
Even though the market pulled back Tuesday and Wednesday, a number of medical stocks continued healthy. Biogen Idec (BIIB) scored a new high in Thursday's session. It's now more than 20% past a 347.85 buy point. In most cases, investors should take...
CNC: 62.83 (-0.42), MNK: 121.33 (-0.37), BIIB: 417.63 (-7.98), AKRX: 49.83 (-1.05), MOH: 61.27 (-1.00)
Today's Momo Momentum Stock Is Biogen Idec (BIIB)
at The Street - Thu Mar 05, 8:56AM CST
Trade-Ideas LLC identified Biogen Idec (BIIB) as a momo momentum candidate
BIIB: 417.63 (-7.98)
Market Is Looking For Positive News - Cramer's Mad Money (3/4/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Mar 05, 6:45AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday, March 4. The market closed lower on Wednesday, but Cramer still thinks the market and stocks will go higher on any positive news. Citing Wayfair's (NYSE: W )...
HYH: 46.26 (+0.79), RH: 89.94 (-0.65), GPRO: 40.13 (-0.95), BIIB: 417.63 (-7.98), BMRN: 113.77 (+0.27), PCYC: 254.56 (+0.34), KMB: 106.82 (-1.64), LLTC: 47.65 (-0.72), BMY: 65.12 (-0.93), ALKS: 68.19 (-3.03), CHRS: 27.48 (-2.23), CELG: 118.03 (-2.68), W: 28.81 (+1.03), ISIS: 70.44 (-1.32), GILD: 101.81 (-1.61), LH: 121.70 (-1.58), MCD: 97.13 (-1.98), REGN: 422.13 (-6.82), BABA: 84.40 (-1.70)
Jim Cramer's Top Takeaways: Wayfair, Honeywell, Halyard Health, More
at The Street - Thu Mar 05, 4:34AM CST
Cramer says that Honeywell is his one of his favorite industrial stocks and that the biotech sector is filled with strong buys, including Regeneron and Celgene.
HYH: 46.26 (+0.79), RH: 89.94 (-0.65), BIIB: 417.63 (-7.98), W: 28.81 (+1.03), HON: 101.87 (-1.26), GILD: 101.81 (-1.61), KMB: 106.82 (-1.64), RRD: 19.48 (+0.21), REGN: 422.13 (-6.82), CELG: 118.03 (-2.68)
Jim Cramer's 'Mad Money' Recap: The Market Is a Battlefield
at The Street - Wed Mar 04, 7:14PM CST
Investors have to pay attention to see what's really worth buying.
RH: 89.94 (-0.65), BIIB: 417.63 (-7.98), BMRN: 113.77 (+0.27), PCYC: 254.56 (+0.34), HON: 101.87 (-1.26), KMB: 106.82 (-1.64), RRD: 19.48 (+0.21), JNJ: 100.11 (-2.41), W: 28.81 (+1.03), SCTY: 50.45 (-1.32), CMG: 658.68 (-11.81), RCPT: 140.09 (-1.10), FL: 59.37 (+2.34), REGN: 422.13 (-6.82), HYH: 46.26 (+0.79), CY: 15.10 (-0.40), SWKS: 90.75 (-0.80), VFC: 74.49 (-1.58), NXPI: 98.48 (-0.19), ALKS: 68.19 (-3.03), CELG: 118.03 (-2.68), WWAV: 41.79 (-0.63), URBN: 38.89 (+0.15), HAIN: 61.66 (-1.03), FSLR: 60.61 (-1.05), GOGO: 20.21 (+0.14), ISIS: 70.44 (-1.32), GILD: 101.81 (-1.61), MCD: 97.13 (-1.98), STM: 9.18 (-0.13), DST: 106.03 (+0.16), BIG: 48.52 (+0.70), AVGO: 127.89 (-2.68)
Top Funds Buying Rackspace, Allergan, Biogen Idec, Apple
at Investor's Business Daily - Tue Mar 03, 5:50PM CST
The nation's top-rated mutual funds the past three months have been big buyers of large medical names such as Allergan (AGN) in their latest reporting periods. IBD's biotech/biomedical group was ranked No. 1 among 197 industries as of Tuesday. Others...
AMZN: 380.09 (-7.74), BIIB: 417.63 (-7.98), MNST: 136.62 (-3.41), HD: 114.45 (-1.46), RAX: 51.14 (-0.21), PCYC: 254.56 (+0.34), SPG: 180.58 (-6.55), ORLY: 204.19 (-3.83), SLXP: 158.01 (+0.57), AGN: 233.51 (-1.90), V: 269.34 (-4.79), LNKD: 264.63 (-3.71), GOOGL: 572.90 (-8.53), LOW: 73.51 (-1.05), HBI: 32.00 (-0.14), ULTA: 138.59 (-2.27), CMCSA: 60.37 (+0.04), AAPL: 126.60 (+0.19), MA: 90.79 (-2.02)
Amgen: The Best Biotech Stock You Don't Own
Dan Strack - at Seeking Alpha - Tue Mar 03, 4:04PM CST
BIIB: 417.63 (-7.98), GILD: 101.81 (-1.61), PFE: 33.97 (-0.50), MRK: 56.84 (-1.14), AMGN: 154.88 (-4.72), ABBV: 55.64 (-1.22), GSK: 46.73 (-0.87), BMY: 65.12 (-0.93), HSP: 87.90 (+0.05), NVS: 97.46 (-1.49), CELG: 118.03 (-2.68)
Nasdaq Hits 5000: 3 Choices to Ride the Upswing - Analyst Blog
Swarup Gupta - Zacks Investment Research - Tue Mar 03, 10:36AM CST
Echoes of the dot-com boom could be heard yesterday after the Nasdaq closed above 5,000 for the first time in 15 years.
AMZN: 380.09 (-7.74), BIIB: 417.63 (-7.98), FB: 80.00 (-1.21), AMGN: 154.88 (-4.72), H: 58.89 (-1.39), INTC: 33.19 (-0.54), PCLN: 1,215.99 (-15.91), CELG: 118.03 (-2.68), SBUX: 92.21 (-1.42), GILD: 101.81 (-1.61), MSFT: 42.36 (-0.75), AAPL: 126.60 (+0.19), CSCO: 28.92 (-0.38), ONNN: 12.90 (-0.14)
Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success, New Report Launched
M2 - Tue Mar 03, 5:18AM CST
Market Research Reports, Inc. has announced the addition of "Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success" research report to their website http://www.MarketResearchReports.com
BIIB: 417.63 (-7.98), AMGN: 154.88 (-4.72)
Big Cap 20 Reflecting Market Leadership
at Investor's Business Daily - Mon Mar 02, 5:44PM CST
The Big Cap 20 is showing itself to be a good representation of today's market leadership, as technology, health care and consumer stocks dominate the list. A glance of the IBD Smart NYSE + Nasdaq Tables shows chips, medical, apparel, retail and...
SBUX: 92.21 (-1.42), CI: 120.57 (-1.94), BIIB: 417.63 (-7.98), VRX: 198.71 (-5.24), QRVO: 72.98 (-1.53), PCYC: 254.56 (+0.34), ORLY: 204.19 (-3.83), UNH: 112.88 (-1.91), ADI: 57.93 (-0.52), MYL: 55.44 (-1.25), AAPL: 126.60 (+0.19), ROST: 104.40 (-0.55)
After Yesterday's Rally of 1.51% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Mar 02, 3:49PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $406.40 to a high of $416.82. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $412.02 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 417.63 (-7.98)
Biogen/Sobi Report Postive Phase III Data on Alprolix - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 02, 1:10PM CST
Biogen (BIIB) and Sobi together announced positive results from a phase III study on their hemophilia B drug, Alprolix.
BIIB: 417.63 (-7.98), CBM: 33.77 (-0.63), ISIS: 70.44 (-1.32), THRX: 19.60 (-0.26)
Biogen Idec: A Great Company, But Not An Alpha Opportunity
Lee Taylor - at Seeking Alpha - Mon Mar 02, 11:39AM CST
BIIB: 417.63 (-7.98), SAN: 6.98 (-0.21), ALXN: 181.65 (-4.14), NVS: 97.46 (-1.49)
Could This Study Help Lead to a Cure for Select Multiple Sclerosis Patients?
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 08, 8:12AM CDT
Source: National Multiple Sclerosis Society, Facebook For a disease that affects 2.5 million people around the globe and more than 400,000 people in the United States, it's a shame that so little is known about multiple sclerosis despite the amount...
BIIB: 417.63 (-7.98), RCPT: 140.09 (-1.10)
2 Tiny Biotechs That Could Have Blockbuster Opportunity
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Sat Mar 07, 9:11AM CST
Smaller health care stocks are not for the faint of heart. When it comes to developing and testing new drugs, the success rate is tiny but the rewards can be huge. How can the risk-tolerant Fool spot the next Amgen or Biogen ? This health care...
JNJ: 100.11 (-2.41), BIIB: 417.63 (-7.98), PTLA: 41.72 (-0.13), PFE: 33.97 (-0.50), OPHT: 53.19 (-0.29), AMGN: 154.88 (-4.72), BMY: 65.12 (-0.93), NVS: 97.46 (-1.49), CELG: 118.03 (-2.68)
Top 5 IBD 50 Drug Stocks Thriving Via Acquisitions
at Investor's Business Daily - Sat Mar 07, 7:02AM CST
The recent flurry of deal-making in the drug sector has put the spotlight on other top-rated drugmakers that have grown with the help of savvy mergers and acquisitions. In just the past week, AbbVie (ABBV) agreed to buy Pharmacyclics (PCYC) for $21...
AGN: 233.51 (-1.90), MNK: 121.33 (-0.37), JNJ: 100.11 (-2.41), BIIB: 417.63 (-7.98), ACT: 289.92 (-5.78), VRX: 198.71 (-5.24), PCYC: 254.56 (+0.34), OMED: 27.55 (-0.12), AKRX: 49.83 (-1.05), SLXP: 158.01 (+0.57), ABBV: 55.64 (-1.22), CELG: 118.03 (-2.68)
ISIS Pharmaceuticals Has The Cash To Develop Its Expanding Product Pipeline
Emerging Equities - at Seeking Alpha - Fri Mar 06, 4:03PM CST
BIIB: 417.63 (-7.98), ISIS: 70.44 (-1.32), IBB: 342.36 (-5.31), GSK: 46.73 (-0.87), ETF: 12.82 (-0.18)
Stock Market News for March 06, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Mar 06, 9:10AM CST
Markets snapped a two-day losing streak on Thursday, somewhat boosted by the ECB announcing a trillion-dollar stimulus plan that will kick off on Monday
BIIB: 417.63 (-7.98), JNJ: 100.11 (-2.41), PCYC: 254.56 (+0.34), ADP: 86.00 (-0.75), MDT: 76.48 (-2.02), GILD: 101.81 (-1.61), ABBV: 55.64 (-1.22), BMY: 65.12 (-0.93)
Isis Pharma earns $9M milestone from Biogen
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 8:28AM CST
BIIB: 417.63 (-7.98), ISIS: 70.44 (-1.32)
5 Top Medical Stocks: How To Read Their Chart Action
at Investor's Business Daily - Thu Mar 05, 5:32PM CST
Even though the market pulled back Tuesday and Wednesday, a number of medical stocks continued healthy. Biogen Idec (BIIB) scored a new high in Thursday's session. It's now more than 20% past a 347.85 buy point. In most cases, investors should take...
CNC: 62.83 (-0.42), MNK: 121.33 (-0.37), BIIB: 417.63 (-7.98), AKRX: 49.83 (-1.05), MOH: 61.27 (-1.00)
Today's Momo Momentum Stock Is Biogen Idec (BIIB)
at The Street - Thu Mar 05, 8:56AM CST
Trade-Ideas LLC identified Biogen Idec (BIIB) as a momo momentum candidate
BIIB: 417.63 (-7.98)
Market Is Looking For Positive News - Cramer's Mad Money (3/4/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Mar 05, 6:45AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday, March 4. The market closed lower on Wednesday, but Cramer still thinks the market and stocks will go higher on any positive news. Citing Wayfair's (NYSE: W )...
HYH: 46.26 (+0.79), RH: 89.94 (-0.65), GPRO: 40.13 (-0.95), BIIB: 417.63 (-7.98), BMRN: 113.77 (+0.27), PCYC: 254.56 (+0.34), KMB: 106.82 (-1.64), LLTC: 47.65 (-0.72), BMY: 65.12 (-0.93), ALKS: 68.19 (-3.03), CHRS: 27.48 (-2.23), CELG: 118.03 (-2.68), W: 28.81 (+1.03), ISIS: 70.44 (-1.32), GILD: 101.81 (-1.61), LH: 121.70 (-1.58), MCD: 97.13 (-1.98), REGN: 422.13 (-6.82), BABA: 84.40 (-1.70)
Jim Cramer's Top Takeaways: Wayfair, Honeywell, Halyard Health, More
at The Street - Thu Mar 05, 4:34AM CST
Cramer says that Honeywell is his one of his favorite industrial stocks and that the biotech sector is filled with strong buys, including Regeneron and Celgene.
HYH: 46.26 (+0.79), RH: 89.94 (-0.65), BIIB: 417.63 (-7.98), W: 28.81 (+1.03), HON: 101.87 (-1.26), GILD: 101.81 (-1.61), KMB: 106.82 (-1.64), RRD: 19.48 (+0.21), REGN: 422.13 (-6.82), CELG: 118.03 (-2.68)
Jim Cramer's 'Mad Money' Recap: The Market Is a Battlefield
at The Street - Wed Mar 04, 7:14PM CST
Investors have to pay attention to see what's really worth buying.
RH: 89.94 (-0.65), BIIB: 417.63 (-7.98), BMRN: 113.77 (+0.27), PCYC: 254.56 (+0.34), HON: 101.87 (-1.26), KMB: 106.82 (-1.64), RRD: 19.48 (+0.21), JNJ: 100.11 (-2.41), W: 28.81 (+1.03), SCTY: 50.45 (-1.32), CMG: 658.68 (-11.81), RCPT: 140.09 (-1.10), FL: 59.37 (+2.34), REGN: 422.13 (-6.82), HYH: 46.26 (+0.79), CY: 15.10 (-0.40), SWKS: 90.75 (-0.80), VFC: 74.49 (-1.58), NXPI: 98.48 (-0.19), ALKS: 68.19 (-3.03), CELG: 118.03 (-2.68), WWAV: 41.79 (-0.63), URBN: 38.89 (+0.15), HAIN: 61.66 (-1.03), FSLR: 60.61 (-1.05), GOGO: 20.21 (+0.14), ISIS: 70.44 (-1.32), GILD: 101.81 (-1.61), MCD: 97.13 (-1.98), STM: 9.18 (-0.13), DST: 106.03 (+0.16), BIG: 48.52 (+0.70), AVGO: 127.89 (-2.68)
Top Funds Buying Rackspace, Allergan, Biogen Idec, Apple
at Investor's Business Daily - Tue Mar 03, 5:50PM CST
The nation's top-rated mutual funds the past three months have been big buyers of large medical names such as Allergan (AGN) in their latest reporting periods. IBD's biotech/biomedical group was ranked No. 1 among 197 industries as of Tuesday. Others...
AMZN: 380.09 (-7.74), BIIB: 417.63 (-7.98), MNST: 136.62 (-3.41), HD: 114.45 (-1.46), RAX: 51.14 (-0.21), PCYC: 254.56 (+0.34), SPG: 180.58 (-6.55), ORLY: 204.19 (-3.83), SLXP: 158.01 (+0.57), AGN: 233.51 (-1.90), V: 269.34 (-4.79), LNKD: 264.63 (-3.71), GOOGL: 572.90 (-8.53), LOW: 73.51 (-1.05), HBI: 32.00 (-0.14), ULTA: 138.59 (-2.27), CMCSA: 60.37 (+0.04), AAPL: 126.60 (+0.19), MA: 90.79 (-2.02)
Amgen: The Best Biotech Stock You Don't Own
Dan Strack - at Seeking Alpha - Tue Mar 03, 4:04PM CST
BIIB: 417.63 (-7.98), GILD: 101.81 (-1.61), PFE: 33.97 (-0.50), MRK: 56.84 (-1.14), AMGN: 154.88 (-4.72), ABBV: 55.64 (-1.22), GSK: 46.73 (-0.87), BMY: 65.12 (-0.93), HSP: 87.90 (+0.05), NVS: 97.46 (-1.49), CELG: 118.03 (-2.68)
Nasdaq Hits 5000: 3 Choices to Ride the Upswing - Analyst Blog
Swarup Gupta - Zacks Investment Research - Tue Mar 03, 10:36AM CST
Echoes of the dot-com boom could be heard yesterday after the Nasdaq closed above 5,000 for the first time in 15 years.
AMZN: 380.09 (-7.74), BIIB: 417.63 (-7.98), FB: 80.00 (-1.21), AMGN: 154.88 (-4.72), H: 58.89 (-1.39), INTC: 33.19 (-0.54), PCLN: 1,215.99 (-15.91), CELG: 118.03 (-2.68), SBUX: 92.21 (-1.42), GILD: 101.81 (-1.61), MSFT: 42.36 (-0.75), AAPL: 126.60 (+0.19), CSCO: 28.92 (-0.38), ONNN: 12.90 (-0.14)
Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success, New Report Launched
M2 - Tue Mar 03, 5:18AM CST
Market Research Reports, Inc. has announced the addition of "Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success" research report to their website http://www.MarketResearchReports.com
BIIB: 417.63 (-7.98), AMGN: 154.88 (-4.72)
Big Cap 20 Reflecting Market Leadership
at Investor's Business Daily - Mon Mar 02, 5:44PM CST
The Big Cap 20 is showing itself to be a good representation of today's market leadership, as technology, health care and consumer stocks dominate the list. A glance of the IBD Smart NYSE + Nasdaq Tables shows chips, medical, apparel, retail and...
SBUX: 92.21 (-1.42), CI: 120.57 (-1.94), BIIB: 417.63 (-7.98), VRX: 198.71 (-5.24), QRVO: 72.98 (-1.53), PCYC: 254.56 (+0.34), ORLY: 204.19 (-3.83), UNH: 112.88 (-1.91), ADI: 57.93 (-0.52), MYL: 55.44 (-1.25), AAPL: 126.60 (+0.19), ROST: 104.40 (-0.55)
After Yesterday's Rally of 1.51% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Mar 02, 3:49PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $406.40 to a high of $416.82. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $412.02 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 417.63 (-7.98)
Biogen/Sobi Report Postive Phase III Data on Alprolix - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 02, 1:10PM CST
Biogen (BIIB) and Sobi together announced positive results from a phase III study on their hemophilia B drug, Alprolix.
BIIB: 417.63 (-7.98), CBM: 33.77 (-0.63), ISIS: 70.44 (-1.32), THRX: 19.60 (-0.26)
Biogen Idec: A Great Company, But Not An Alpha Opportunity
Lee Taylor - at Seeking Alpha - Mon Mar 02, 11:39AM CST
BIIB: 417.63 (-7.98), SAN: 6.98 (-0.21), ALXN: 181.65 (-4.14), NVS: 97.46 (-1.49)
